Alimta for Mesothelioma to Be Available on Expanded Access Basis

September 1, 2002

INDIANAPOLIS-Based on phase III trial results presented at ASCO (see ONI, July 2002, page 1), Eli Lilly and Company and the US Food and Drug Administration have reached an agreement to make Alimta (pemetrexed) available on an expanded access, or compassionate use, basis to medically eligible patients with malignant pleural mesothelioma. Lilly is pursuing approval of Alimta in combination with cisplatin (Platinol) for this indication. For more information, physicians may call 1-866-347-9503.

INDIANAPOLISBased on phase III trial results presented at ASCO (see ONI, July 2002, page 1), Eli Lilly and Company and the US Food and Drug Administration have reached an agreement to make Alimta (pemetrexed) available on an expanded access, or compassionate use, basis to medically eligible patients with malignant pleural mesothelioma. Lilly is pursuing approval of Alimta in combination with cisplatin (Platinol) for this indication. For more information, physicians may call 1-866-347-9503.